Refreshed just now
STAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming
Why it’s here: FDA rejection of a cell therapy for Duchenne under regulatory review falls within biotechnology's FDA regulation of novel therapies (cell and gene therapy), a live federal regulatory decision with policy dimensions.
Trace across the boardItem
YesterdaySTATSTAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time comingFDA rejected Capricor Therapeutics' cell therapy deramiocel for Duchenne muscular dystrophy after two randomized trials failed to show efficacy.1 outletBiotech20 linked
Connected
20 links- HillStrategic Planning: FDA Could Further Strengthen Robust IT Modernization PlanBoth involve Food and Drug Administration
- NewsSTAT+: 7 burning questions about the FDA’s post-Overton futureBoth involve Food and Drug Administration
- NewsFDA sets up council for post-market review of vaccines, gene therapiesBoth involve Food and Drug Administration
- NewsFDA warns against online weight-loss drugs containing uncertain ingredientsBoth involve Food and Drug Administration
- NewsUS FDA orders new eye risk warnings for Ozempic, ZepboundBoth involve Food and Drug Administration
- NewsSTAT+: FDA warns GLP-1 drugs carry potential risk of rare eye conditionBoth involve Food and Drug Administration
- HillComments due: Robotically-Assisted Surgical Devices - Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Draft GuidanceBoth involve Food and Drug Administration
- HillComments due: Public Workshop: Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation CapabilitiesBoth involve Food and Drug Administration
- HillComments due: Potency Assessment of Active Immunotherapy Products; Draft Guidance for IndustryBoth involve Food and Drug Administration
- HillComments due: Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities: Discussion Paper and Request for FeedbackBoth involve Food and Drug Administration
- HillComments due: Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management; Draft Guidance for IndustryBoth involve Food and Drug Administration
- HillComments due: FDA Scientific Public Workshop: Next-Generation Sequencing for Adventitious Agent Detection in BiologicsBoth involve Food and Drug Administration
- HillComments due: BsUFA III Future Needs for the Development of Interchangeable Products; Post-Workshop Strategy DocumentBoth involve Food and Drug Administration
- HillCRS Report: Novel Gene Therapies for Blood DisordersBoth involve Food and Drug Administration
- HillEarly-Phase IND Protocol Recommendations for Solid Tumors; Draft Guidance for Industry; AvailabilityBoth involve Food and Drug Administration
- HillComments due: Early-Phase IND Protocol Recommendations for Solid Tumors; Guidance for Industry - Draft GuidanceBoth involve Food and Drug Administration
- HillMoolenaar to FDA: "Chinese Clinical Data Poses Real Risks for Patients"Both involve Food and Drug Administration
- NewsSTAT+: FDA rejects lung cancer treatment ivonescimab from Summit TherapeuticsBoth involve Food and Drug Administration
- MoneyFY27 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory ScienceBoth involve Food and Drug Administration
- MoneyFY27 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory ScienceBoth involve Food and Drug Administration
About
- Food and Drug Administration